Docstoc

WPC Globe.pdf

Document Sample
WPC Globe.pdf Powered By Docstoc
					                            Register by March 13 and Save up to $350!




                                                Cambridge Healthtech Institute’s Eighth Annual




                                                                                                              June 9-11, 2009
    Pre-Conference Short Courses                                Loews Philadelphia Hotel • Philadelphia, PA
    Monday, June 8
    Cardiac Safety: Improving Pre-Clinical                                Drug Discovery Innovation Summit
    Predictions to Better Clinical Outcomes
                                                                                Targeting Pain with Novel Therapeutics
    High Content Screening – Integrated
    Solutions For Accelerated Drug Discovery                                    Targeting Alzheimer’s with Novel Therapeutics
    Avoiding Pitfalls in Alzheimer’s Clinical                                   Cell and Tissue-Based Assays for HTS
    Trial Design
    Ion Channel Assays For Safety Screening
                                                                          Pharmaceutical Strategy Series
    Animal Models of Pain
                                                                                Integrating Effective Alliance Management and
    Premier Sponsors:                                                           Project Management

                                                                          Drug Safety Summit
                                                                          Sponsored by the Drug Safety Executive Council
    Corporate Sponsors:                                                         Cardiotoxicity and Drug Safety
                                                                                Hepatotoxicity and Drug Safety
                                                                                The Expanding Impact of New Animal Models
                                                                                in Drug Safety


                                                                          Lead Sponsoring Publications:


    Corporate Support Sponsor:

                                                                                    Cambridge Healthtech Institute
    Sponsoring Organization:                                                        250 First Avenue, Suite 300, Needham, Massachusetts 02494 • Telephone: 781-972-5400 or
                                                                                    toll-free in the U.S. 888-999-6288 • Fax: 781-972-5425 • www.healthtech.com



3                                                        g
                                           WorldPharmaCongress.com
                                       Pre-Conference Short Courses: June 8, 2009      Hotel Information
                                       Conference: June 9-11, 2009
                                    CONFERENCE-AT-
                                          E
                                   CONFERENCE-AT-A-GLANCEA-GLANCE                   Loews Philadelphia Hotel
                                           MONDAY,
                                           MONDAY JUNE 8
                                           MONDAY JUNE
                                            O                                       1200 Market Street
    8:00 - 9:00 am
                                                                                    Philadelphia, PA 19107
                          Morning Coffee
                                                                                    Phone: 215-627-1200
    8:00 am - 2:00 pm     Pre-Conference Short Course Registration                  Fax: 215-231-7305
    9:00 am - 12:00 pm    Morning Short Courses                                     Discounted Room Rate: $209 s/d
                                                                                    Reduced Room Rate Cutoff: May 18, 2009
    2:00 - 5:00 pm        Afternoon Short Courses
    3:00 - 5:00 pm                                                                  To reserve your hotel room, please
                          Main Conference Pre-Registration
                                                                                    call the hotel directly to make your
                                           TUESDAY, JUNE 9                          room reservation. Identify yourself
    7:30 am - 6:00 pm     Registration Open                                         as a Cambridge Healthtech Institute
                                                                                    conference attendee to receive the
    7:30 - 8:30 am        Morning Coffee
                                                                                    reduced room rate. Reservations made
    8:30 - 10:10 am       Concurrent Tracks                                         after the cut-off date or after the group
    10:10 - 10:40 am      Networking Coffee Break                                   room block has been filled (whichever
                                                                                    comes first) will be accepted on a space-
    10:40 am - 12:10 pm   Concurrent Tracks
                                                                                    and-rate-availability basis. Rooms are
    12:10 - 1:10 pm       Luncheon Presentations                                    limited, please book early.
    1:10 - 1:40 pm        Session Break                                             Reserve your hotel room at the Loews
    1:40 - 2:45 pm                                                                  Philadelphia Hotel and SAVE $100 off
                          Concurrent Tracks
                                                                                    your conference registration!*
    2:45 - 3:00 pm        Sponsored Presentations
                                                                                    * See registration page for details
    3:00 - 3:40 pm        Grand Opening Refreshment Break in the Exhibit Hall
    3:40 - 5:10 pm        Concurrent Tracks
    5:10 - 6:10 pm        Happy Hour in the Exhibit Hall
    6:10 pm               End of Day
                                       WEDNESDAY, JUNE 10
    7:30 am - 5:30 pm     Registration Open
    7:30 - 8:30 am        Continental Breakfast Breakout Discussions
    8:30 - 9:40 am        Concurrent Tracks
    9:40 - 10:10 am       Sponsored Presentations
    10:10 -10:50 am       Networking Coffee Break in the Exhibit Hall
    10:50 am -12:20 pm    Concurrent Tracks
    12:20 - 1:55 pm       Lunch on Your Own
    1:55 - 3:30 pm        Concurrent Tracks
    3:30 - 3:45 pm        Sponsored Presentation
    3:45 - 4:30 pm        Networking Refreshment Break in the Exhibit Hall             Travel Information
    4:30 - 5:30 pm        Concurrent Tracks
    5:30 pm               End of Day
                                                                                    Flight Discounts
                                                                                    To receive a 5% or greater discount on
                                          THURSDAY, JUNE 11                         all American Airline flights please
    8:00 am - 4:00 pm     Registration Open                                         use one of the following methods:
                                                                                    •    Call 1-800-433-1790
    8:00 - 8:30 am        Morning Coffee                                                 (authorization code A4819SS).
    8:30 - 10:10 am       Concurrent Tracks                                         •    Go online at www.aa.com
                                                                                         (enter A4819SS in promotion
    10:10 - 10:55 am      Networking Coffee Break in the Exhibit Hall                    discount box).
    10:55 - 11:55 am                                                                •    Contact our designated
                          Concurrent Tracks
                                                                                         travel agent, Wendy Levine, at
    11:55 am -12:55 pm    Lunch on Your Own                                              1-800-336-5248 ext. 137.
    12:55 - 1:25 pm       Session Break                                             Car Rental Information
    1:25 - 3:00 pm        Concurrent Tracks                                         Special discount rentals have been
    3:00 - 3:40 pm
                                                                                    established with AVIS for this conference.
                          Ice Cream Refreshment Break in the Exhibit Hall
                                                                                    Call AVIS direct at 800-331-1600 and
                          (Last Chance for Viewing)
                                                                                    reference the Avis Worldwide Discount
    3:40 - 5:10 pm        Concurrent Tracks                                         (AWD) Number J868190.
         pm
    5:10 p                Close of Conference


4
2                                                             g
                                                WorldPharmaCongress.com
                                                 Pre-Conference Short Courses*
                                                                           Monday, June 8
 9:00am-12:00pm                                                                          2:00-5:00pm

 (SC1) CARDIAC SAFETY: IMPROVING PRE-CLINICAL                                            (SC4) ION CHANNEL ASSAYS FOR SAFETY SCREENING
       PREDICTIONS TO BETTER CLINICAL OUTCOMES
                                                                                         Ion channels are involved in a complex and intricate signaling
 Cardiotoxicity is one of the major forms of drug toxicity and accounts                  system that plays an important role in affecting the cellular response
 for most recalls and delays experienced in drug approvals. One of the                   to a drug, and hence, to overall patient safety. Drug-Induced
 biggest challenges is how to predict cardiac risk early and accurately                  alterations in the translation and trafficking of ion channel proteins
 in the drug development process. This course will provide an                            and drug-induced blockade of channels are all thought to contribute
 overview of the recent technical and scientific advances in pre-clinical                 to drug-related adverse events. In vitro assays using isolated cells,
 and clinical safety testing, such as improvements in assay design                       cell lines, and expression systems cloned for specific ion channels
 and reagents, use of new cell lines and animal models for toxicity                      are now routinely used, alongside electrophysiology experiments,
 screening and the use of biomarkers for determining cardiac safety.                     to identify potential drug liabilities. This course provides a detailed
 The discussion is intended to get researchers and clinicians thinking                   overview of the types of ion channel-based screening assays and
 about ways to improve the predictors of cardiac safety by effectively                   technologies that are currently in use and how they are being
 combining the intelligence gathered from pre-clinical screens, with                     applied to effectively monitor and predict drug safety. This course
 clinical data and post-marketing pharmacovigilance studies. This                        provides you with an overview of current and emerging ion channel-
 course provides you with the information to question the validity of                    based assays and when and how to use them.
 the tools for cardiac assessment that are in use today.                                 Course Instructors:
 Course Instructor:                                                                      Gary Gintant, Ph.D., Senior Group Leader, Integrative Pharmacology, Abbott Laboratories
 J. Rick Turner, Ph.D., PGCE, President and Chief Scientific Officer, Turner Medical
                                                                                         Harry Witchel, Ph.D., Senior Lecturer in Physiology, Brighton and Sussex Medical School
 Communications LLC

                                                                                         (SC6) ANIMAL MODELS OF PAIN
 (SC2) HIGH CONTENT SCREENING – INTEGRATED
       SOLUTIONS FOR ACCELERATED DRUG DISCOVERY                                          Many are frustrated with the lack of translational progress in the
                                                                                         pain field, in which huge gains in basic science knowledge obtained
 High Content Screening (HCS) has become an increasingly powerful
                                                                                         using animal models have not led to the development of many
 tool for cell-based target validation, screening, and lead optimization,
                                                                                         novel, clinically effective compounds. A careful reexamination
 and has enabled the application of sophisticated assays for large-
                                                                                         of animal models of pain is therefore warranted. In this course, I
 scale compound screening. We will examine how HCS has evolved
                                                                                         will describe the current implementation of animal models of pain,
 into an integrated solution for accelerated drug discovery. We will
                                                                                         discuss a wide range of modulatory factors affecting data obtained
 look at the workflow components of HCS, including assay design,
                                                                                         within them, lay out the case for the replacement of current models
 instrumentation for automated fixed-end-point assays and examine
                                                                                         by more sophisticated ones, and describe progress toward that goal.
 the application and benefits of HCS in live cell kinetic analysis. We
                                                                                         Course Instructor:
 will also examine advanced BioApplications that produce information
 on drug responses from cell image data, informatics/bioinformatics                      Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies, Canada Research Chair
 solutions and how to deal with data-management issues related to                        in Genetics of Pain, Dept. of Psychology and Centre for Research on Pain,
 HCS. This course provides you with a foundation in high-content                         McGill University
 screening and its applications.
 Course Instructors:                                                                     *Separate registration required
 Jie Zheng, Ph.D., Associate Professor, Physiology and Membrane Biology, University of
 California at Davis School of Medicine
 Neal Gliksman, Senior Applications Scientist, Molecular Devices

 (SC3) AVOIDING PITFALLS IN ALZHEIMER’S
       CLINICAL TRIAL DESIGN
 The design of clinical trials for Alzheimer’s therapeutics has
 historically suffered from many pitfalls. These include adequate
 evaluation of cognitive and functional decline, choosing biomarkers
 as indices of drug activity and disease progression, and aspects of
 phase 2 and phase 3 design. Although clinical outcome measures
 remain the gold standard, attention to implementation, and additional
 use of biomarkers will help to clarify drug effects.
 Course Instructor:
 Douglas R. Galasko, Ph.D., Professor in Residence, University of California-San Diego




Web Partners:



                                                                           g
                                                             WorldPharmaCongress.com                                                                                               3
                                                                                                                           Second Annual
                                                                      Targeting Pain with Novel Therapeutics
                                                                                                             Leading the Chase to the Clinic
                                                                                                                            June 9-10
Drug Discovery Innovation Summit



                                                                MONDAY
                                                                MONDAY, JUNE 8                                                     2:45     Sponsored Presentation (Opportunity Available)
                                             RECOMMENDED PRE-CONFERENCE SHORT COURSE*                                              3:00     Grand Opening Refreshment Break in the Exhibit Hall
                                     2:00 – 5:00 pm                                                                                3:40     Analgesic Effects of a Potent & Selective Kinase-Inhibitor
                                     (SC6) ANIMAL MODELS OF PAIN                                                                            of Neurotrophin Receptors TrkA, TrkB and TrkC in a Model of
                                     See page 2 for details and a full list of short courses.    *Separate Registration Required            Inflammatory Pain
                                                                                                                                   Steven W. Andrews, Ph.D., Associate Director of Drug Discovery, Array BioPharma Inc.
                                     3:00 – 5:00pm Main Conference Pre-Registration
                                                                                                                                   4:10     Targeting Peripheral Analgesia
                                   MAIN CONFERENCE                                                                                 Robert Spencer, Ph.D., Senior Director, Preclinical Development, Cara Therapeutics, Inc.

                                                               TUESDAY, JUNE 9                                                     4:40     Talk Title to be Announced
                                                                                                                                   Thierry Groblewski, Ph.D., AstraZeneca R&D
                                   7:30 am – 6:00 pm Registration Open
                                   7:30     Morning Coffee                                                                         5:10     Happy Hour in the Exhibit Hall
                                                                                                                                   6:10     End of Day
                                                                 TARGETING TRPV                                                                         WEDNESDAY, JUNE 10
                                   8:30     Chairperson’s Remarks                                                                  7:30 am – 5:30 pm Registration Open
                                   Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies, Canada Research Chair in
                                   Genetics of Pain, Dept. of Psychology and Centre for Research on Pain,                          7:30 – 8:30 Continental Breakfast Breakout Discussions
                                   McGill University                                                                               Table One: Animal Models of Pain
                                                                                                                                   Moderator: Steven W. Andrews, Ph.D., Associate Director of Drug Discovery, Array
                                   8:40     The Genetics of Pain                                                                   BioPharma Inc.
                                   Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies, Canada Research Chair in
                                   Genetics of Pain, Dept. of Psychology and Centre for Research on Pain,                          •   Translation from Preclinical to the Clinic
                                   McGill University                                                                               •   Biomarkers
                                                                                                                                   •   Successful Strategies
                                   9:10     The Evolution of Thiazolo[5,4-d]pyrimidines and Related
                                            Heterocycles as TRPV1 Antagonists                                                      Table Two: Targeting FAAH and Cannabinoids
                                   Alec D. Lebsack, Ph.D., Senior Scientist, Medicinal Chemistry, Johnson & Johnson                Moderator: J. Guy Breitenbucher, Ph.D., Research Fellow, Team Leader, Pain and Related
                                   Pharmaceutical Research & Development                                                           Disorders, Johnson & Johnson Pharmaceutical Research & Development
                                                                                                                                   •   Discovery of Highly Selective Urea FAAH Inhibitors
                                   9:40     Discovery of 3-carboxamide Isoxazoles as TRPV1 Antagonists
                                            for the Treatment of Pain                                                              •   Preclinical Models
                                   Paul D. Ratcliffe, Ph.D., Research Scientist, Team Leader, Schering-Plough Corporation          •   Computational Approaches

                                   10:10 Networking Coffee Break                                                                   Table Three: Targeting Inflammatory Pain
                                                                                                                                   Moderator: Moderator to be Announced
                                                                 TARGETING FAAH                                                    •   Selective Inhibitors
                                                                                                                                   •   Animal Models
                                   10:40 Fatty Acid Amide Hydrolase (FAAH): A Look in the Rear-View                                •   Progress with FAAH, Trk and Beyond
                                         Mirror, Perspectives on Reversibility
                                   J. Guy Breitenbucher, Ph.D., Research Fellow, Team Leader, Pain and Related Disorders,
                                   Johnson & Johnson Pharmaceutical Research & Development
                                                                                                                                          SODIUM AND POTASSIUM CHANNELS
                                   11:10    Discovery of Highly Selective Urea FAAH Inhibitors that Reduce                         8:30     Chairperson’s Remarks
                                            Inflammatory Pain                                                                       8:40     FEATURED PRESENTATION:
                                   Douglas S. Johnson, Ph.D., Senior Principal Scientist, Medicinal Chemistry, Pfizer Global                 Nav1.7 Inhibitors – Discovery and Development
                                   Research & Development                                                                          Joseph L. Duffy, Ph.D., Director of Medicinal Chemistry, Merck Research Laboratories
                                   11:40 Harnessing the Endogenous Cannabinoid System to Treat                                     9:10     Drug Discovery Targeting CRAC Channels
                                         Inflammatory and Neuropathic Pain                                                          Kenneth A. Stauderman, Ph.D., Vice President, Research, CalciMedica, Inc.
                                   Aron H. Lichtman, Ph.D., Associate Professor, Pharmacology & Toxicology, Virginia
                                   Commonwealth University                                                                         9:40     A Selective Inhibitor of PKC is Efficacious in a Broad Range of
                                                                                                                                            Inflammatory and Neuropathic Pain Models
                                   12:10 pm LUNCHEON PRESENTATION                                                                  Stephen D. Harrison, M.A., Ph.D., Senior Vice President, Research, KAI Pharmaceuticals
                                               Sponsorship Opportunity Available or Lunch on Your Own                              Inc.
                                   1:10     Session Break                                                                          10:10 Networking Coffee Break in the Exhibit Hall
                                                                                                                                   10:50 Speaker and Talk Title to be Announced
                                               TARGETING THE PURINERGIC
                                             RECEPTOR, INFLAMMATORY PAIN,                                                                 ACTIVE PEPTIDES AND NEUROTOXINS
                                                  AND PAIN SIGNALING                                                               11:20 Development of a Novel Orally Active Peptide for the
                                   1:40     Chairperson’s Remarks                                                                        Treatment of Neuropathic Pain
                                   Ronald C. Hawley, Ph.D., Principal Research Scientist, Medicinal Chemistry, Roche Palo Alto     David Craik, Ph.D., Professor, Institute for Molecular Bioscience, The University of
                                                                                                                                   Queensland
                                   1:45     Development of a New Class of Dual P2X3/P2X2/3 Antagonists
                                            for the Treatment of Pain                                                              11:50 Cleavage of SNARE Proteins and Novel Analgesics
                                   Ronald C. Hawley, Ph.D., Principal Research Scientist, Medicinal Chemistry, Roche Palo Alto     Keith Foster, M.A., Ph.D., Founder and Head of Technology Development, Syntaxin Limited

                                   2:15     Purinergic Mechanisms in Chronic Pain: Insights from Receptor-                         12:20 pm Close of Targeting Pain with Novel Therapeutics Conference
                                            Selective Antagonists Studies
                                   Diana Donnelly-Roberts, Ph.D., Research Investigator, Neuroscience, Abbot Laboratories




4                                                                                                             g
                                                                                                WorldPharmaCongress.com
                                                                                           Inaugural
                       Targeting Alzheimer’s with Novel Therapeutics
                                         Delivering Preclinical to Clinical Candidates for an Unmet Medical Need




                                                                                                                                                                                            Drug Discovery Innovation Summit
                                                                                       June 10-11
                             MONDAY, JUNE 8                                                     11:55 LUNCHEON PRESENTATION
          RECOMMENDED PRE-CONFERENCE SHORT COURSE*                                                         Sponsorship Opportunity Available or Lunch on Your Own
  9:00 am – 12:00 pm                                                                            12:55 pm Session Break
  (SC3) AVOIDING PITFALLS IN ALZHEIMER’S CLINICAL TRIAL
        DESIGN                                                                                                NEW AND EMERGING TARGETS
  See page 2 for details and a full list of short courses.   *Separate Registration Required    1:25       Chairperson’s Remarks
                                                                                                Varghese John, Ph.D., Director, Alzheimer’s Drug Discovery Network, The Buck Institute
MAIN CONFERENCE                                                                                 1:30       Novel Therapeutic Approaches Based on APP Signaling
                                                                                                Varghese John, Ph.D., Director, Alzheimer’s Drug Discovery Network, The Buck Institute
                       WEDNESDAY, JUNE 10
                                                                                                2:00       Leptin as a Novel Alzheimer’s Disease Therapeutic
                      AMYLOID APPROACHES                                                        Steven J. Greco, Ph.D., Senior Scientist, Neurotez, Inc.

                                                                                                2:30       TNF Modulation for Treatment of Alzheimer’s Disease
1:55     Chairperson’s Remarks
                                                                                                Edward Tobinick, M.D., Director, Medicine, Institute for Neurological Research, A Private
Sharon Shacham, Ph.D. Vice President of Drug Development, Epix Pharmaceutical
                                                                                                Medical Group, Inc.
2:00     Brain Mitochondria as a Primary Target in the Development of
                                                                                                3:00       Ice Cream Refreshment Break in the Exhibit Hall (Last Chance
         Treatment Strategies for Alzheimer Disease
                                                                                                           for Viewing)
Gjumrakch Aliev, Ph.D., Associate Professor, Cardiovascular and Neuropathology &
Biology, University of Texas - San Antonio                                                      3:40       Small Molecule Effects on Proliferation and Differentiation of
                                                                                                           Adult Neural Stem Cells
2:30     Behavioral Deficits and Plaque Deposition in a Gene-Targeted                            Gilbert Rishton, Ph.D., Channel Island’s Alzheimer’s Institute
         Mouse Model of Alzheimer’s Disease
John Ciallella, Ph.D., Director of Research Operations, Mellior Discovery                       4:10       Dimebon: Turning an Old Drug to a New Use
                                                                                                Fong Wang, M.D., Ph.D., Director, Medivation, Inc.
3:00     Blocking RTN3 Aggregation as a Therapeutic Target of
         Alzheimer’s Treatment                                                                  4:40       Lead Identification of Acetylcholinesterase Inhibitors–
Riqiang Yan, Ph.D., Associate Professor, Neurosciences, Cleveland Clinic Lerner                            Histamine H3 Receptor Antagonists from Molecular Modeling
Research Institute                                                                              Scott D. Bembenek, Ph.D., Senior Scientist, Computer Aided Drug Discovery, Johnson &
                                                                                                Johnson PRD, LLC
3:30     Sponsored Presentation (Opportunity Available)
                                                                                                5:10       Close of Targeting Alzheimer’s with Novel Therapeutics
3:45     Networking Refreshment Break in the Exhibit Hall
4:30     PRX-03140: A Novel, Highly Selective, Small-Molecule
         Agonist of a Specific GPCR Known as 5-HT4
Sharon Shacham, Ph.D. Vice President of Drug Development, Epix Pharmaceutical

5:00     Will β Amyloid Continue to Be a Feasible Alzheimer’s Target?
Interactive Panel Discussion with all Session Speakers

5:30     End of Day
                         THURSDAY, JUNE 11
                                                                                                      Reasons You Should Present Your Research
8:00 am – 4:00 pm Registration Open
                                                                                                    Poster at CHI’s World Pharmaceutical Congress
8:00     Morning Coffee

                             TAU APPROACHES                                                            •     Receive $50 off your registration fee
                                                                                                       •     Your poster abstract will be published on the
8:30     Chairperson’s Remarks
Timothy A. Esbenshade, Ph.D., Senior Group Leader, Abbott Laboratories                                       conference CD
8:40     Potential Efficacy of Tau Aggregation Inhibitor Therapy with                                   •     Your research will be seen by a cross section of R&D
         RemberTM in Alzheimer’s Disease                                                                     leaders from top pharmaceutical, biotech,
Claude M. Wischik, Ph.D., Professor Old Age Psychiatry University of Aberdeen and                            academic and government institutes
Chairman TauRx Therapeutics
                                                                                                       Poster Submission Deadline is May 1, 2009
9:10     Apolipoprotein-E Mimetics Increase PP2a and Reduce
         Alzheimer’s Pathology
Michael Vitek, Ph.D., Chief Executive Officer, Neurology and Neuroscience, Cognosci, Inc.
                                                                                                    Sponsoring Publications:
9:40     Tau Phosphorylation and Synaptic Degeneration
Frank Striggow, Ph.D., KeyNeurotek Pharmaceuticals AG

10:10 Networking Coffee Break in the Exhibit Hall
10:55 Pathways Leading to Alzheimer’s Disease
Maria L. Maccecchini, Ph.D., President and CEO, QR Pharma

11:25 The Histamine H3 Receptor: An Attractive Target for the
      Treatment of Cognitive Disorders
Timothy A. Esbenshade, Ph.D., Senior Group Leader, Neuroscience Research, Global
Pharmaceutical Research & Development, Abbott Laboratories




                                                                             g
                                                               WorldPharmaCongress.com                                                                                                                5
                                                                                                                            Fifth Annual
                                                                         Cell and Tissue-Based Assays for HTS
                                                                                                      The Right Approach for the Right Assay
                                                                                                                  June 9-10
Drug Discovery Innovation Summit



                                                               MONDAY
                                                               MONDAY, JUNE 8                                                     4:10     Novel Assays and New Technologies
                                            RECOMMENDED PRE-CONFERENCE SHORT COURSE*                                              Kalpana Patel, Ph.D., Investigator, Cell Technology, GlaxoSmithKline
                                    9:00 am – 12:00 pm                                                                            4:40     New Mini-Tumor Bioassay Systems to Identify Drug Candidates
                                    (SC2      HIGH CONTENT SCREENING – INTEGRATED SOLUTIONS                                       Raj Singh, Ph.D., President & Chief Executive Officer, R&D, Vivo Biosciences, Inc.
                                              FOR ACCELERATED DRUG DISCOVERY
                                    See page 2 for details and a full list of short courses.    *Separate Registration Required
                                                                                                                                  5:10     Happy Hour in the Exhibit Hall
                                                                                                                                  6:10     End of Day
                                    3:00 – 5:00pm Main Conference Pre-Registration
                                                                                                                                                      WEDNESDAY, JUNE 10
                                   MAIN CONFERENCE                                                                                7:30 am – 5:30 pm Registration Open
                                                               TUESDAY, JUNE 9                                                    7:30 – 8:30 Continental Breakfast Breakout Discussions
                                   7:30 am – 6:00 pm Registration Open                                                            Table Four: Choosing the Right System and Approach for Each Assay
                                                                                                                                  Moderator: Lisa Minor, Ph.D., Principal Scientist, Drug Discovery, Johnson & Johnson
                                   7:30     Morning Coffee
                                                                                                                                  •   Selecting the Right Approach for your Objectives
                                       THE RIGHT PLATFORM AND APPROACH                                                            •   Cell Line Selection
                                              FOR THE RIGHT ASSAY                                                                 Table Five: Label-Free Cell-Based Assays in Early Drug Discovery
                                                                                                                                  Moderator: Ryan McGuinness, Senior Application Scientist, Drug Discovery, MDS
                                   8:30     Chairperson’s Remarks                                                                 Analytical Technologies
                                   Lisa Minor, Ph.D., Principal Scientist, Drug Discovery, Johnson & Johnson                      •   Major Label-Free Technologies Available Today
                                   8:40     Cell-Based Assays in Drug Discovery – So Many Choices, So                             •   Applications Enabled By Label-Free Technologies
                                            Little Time                                                                           •   Benefits Of Label-Free Technologies In The Drug Discovery Workflow
                                   Lisa Minor, Ph.D., Principal Scientist, Drug Discovery, Johnson & Johnson
                                                                                                                                  Table Six: Novel Assays, New Technologies and their Applications
                                   9:10         Designing the Right Strategy to Identify Active Compounds and Test                Moderator: Kalpana Patel, Ph.D., Investigator, Cell Technology, GlaxoSmithKline
                                                a Hypothesis                                                                      •   GCPR and Intra-Celluar and Inter- and Cellular Responses
                                   Taosheng Chen, Ph.D., Director, Assistant Member, Chemical Biology and Therapeutics,           •   Kinases
                                   St. Jude Children’s Research Hospital                                                          •   Cytotoxicity Assays
                                   9:40         Latest Advancements in Calcium
                                                Detection for FLIPR® Assays   Sponsored by                                                  CELL AND TISSUE-BASED ASSAYS
                                   Catherine Parrish, Applications Scientist, Drug Discovery,
                                   Molecular Devices Corporation
                                                                                                                                              APPLICATIONS AND TARGETS
                                   10:10 Networking Coffee Break                                                                  8:30     Chairperson’s Remarks
                                   10:40 A Novel Platform for High-Throughput Gene Expression                                     8:40     Killing One Bird with Two Stones - A Platform for Testing
                                         Profiling                                                                                          Putative Anti-Cancer Agents in Combination using Cell-Based
                                   Andreas Jeromin, Ph.D., Manager, Methods Development, Allen Institute for Brain Science                 Assays
                                                                                                                                  Sharon Zhao, Ph.D., Senior Scientist, Lead Discovery, Amgen, Inc.
                                   11:10    Use of Novel High-Content Assays to Screen Disease-Relevant
                                            Cellular Models of Huntington’s Disease                                               9:10     Developing High Quality Assays for Screening 2.5 Million
                                   Stefan Jaeger, Ph.D., Senior Scientist, Cellular Assays, Evotec AG                                      Compounds
                                                                                                                                  Elisabeth Pook, Ph.D., Senior Scientist, Lead Discovery, Bayer Schering Pharma AG
                                   11:40 Data Analysis in RNAi High-Throughput Screens
                                   Xiaohua Douglas Zhang, Associate Director, Merck Research Laboratories                         9:40     Kinetic Cell-Based Morphological Screening: Prediction of
                                                                                                                                           Mechanism of Compound Action and Off-Target Effects
                                   12:10 pm LUNCHEON PRESENTATION                                                                 Yama Abassi, Ph.D., Senrior, Director, Cell Biology, Roche/ACEA
                                                Sponsorship Opportunity Available or Lunch on Your Own
                                   1:10     Session Break                                                                         10:10 Networking Coffee Break in the Exhibit Hall
                                                                                                                                  10:50 High-Throughput Cell-Based Assays for Pharmacological
                                      LABEL-FREE PLATFORMS AND NOVEL                                                                    Chaperones
                                                                                                                                  Elfrida Benjamin, Ph.D., Principal Investigator, Pharmacology, Amicus Therapeutics
                                    ASSAYS,TECHNOLOGIES & APPLICATIONS
                                                                                                                                  11:20 Screening Bone Marrow Toxicity Using a Tiered Approach
                                   1:40     Chairperson’s Remarks                                                                 David Brott, Ph.D., Principal Scientist, Safety Assessment, AstraZeneca Pharmaceuticals
                                   Ryan McGuinness, Senior Application Scientist, Drug Discovery, MDS Analytical
                                   Technologies                                                                                   11:50 BBB In-Vitro Model to Improve Accuracy in Drug Safety
                                                                                                                                        Assessment
                                   1:45         Matching Label-Free Functional Assays                                             Dorothée Hallier-Vanuxeem, Ph.D, Development Manager, R&D, Cellial Technologies
                                                with Primary Cell Types        Sponsored by
                                   Ryan McGuinness, Senior Application Scientist, Drug Discovery,                                 12:20 pm Close of Cell and Tissue-Based Assays for HTS Conference
                                   MDS Analytical Technologies
                                   2:15     Label-Free Imaging
                                   Charles River Laboratories, Speaker to be Announced

                                   2:45     Sponsored Presentation (Opportunity Available)
                                   3:00     Grand Opening Refreshment Break in the Exhibit Hall
                                   3:40     Evaluation of Putative GPCR Antagonists Using the
                                            CellKey System
                                   David J. Bell, Department of Automated Biotechnology, Merck & Company




6                                                                                                            g
                                                                                               WorldPharmaCongress.com
                                                                                      Inaugural
Integrating Effective Alliance Management and Project Management
                                            Effective Strategies, Tools and Tactics for Better Collaborations
                                                                      June 10-11




                                                                                                                                                                                       Pharmaceutical Strategy Series
                    WEDNESDAY, JUNE 10                                                       11:25 Bayer Healthcare
                                                                                             Speaker to be Announced
          HOW TO ORGANIZE AND MANAGE                                                         11:55 LUNCHEON PRESENTATION
              THE AM-PM INTERFACE                                                                     Sponsorship Opportunity Available or Lunch on Your Own
                                                                                             12:55 pm Session Break
1:55     Chairperson’s Remarks
Kendra Eager, Ph.D., Assistant Vice President, Alliance Management, Wyeth                      COORDINATION, COMMUNICATIONS AND
Pharmaceuticals
                                                                                                    KNOWLEDGE MANAGEMENT
2:00     Project Management and Alliance Management - Working as a
         Team                                                                                1:25     Chairperson’s Remarks
Kendra Eager, Ph.D., Assistant Vice President, Alliance Management, Wyeth                    Jeremy Ahouse, Ph.D., Director, Alliance Management, Novartis Institutes for Biomedical
Pharmaceuticals                                                                              Research, Inc.

2:30     Tools, Tactics and Best Practices - Alliance Management and                         1:30     Project Management Execution in Alliances with Biotech
         Project Management in Biotech Companies                                                      Company Partners
Michael F. Haller, Vice President of Alliance Management and Portfolio Development,          David Hauser, Executive Director, Alliance Management, NovaQuest (The Partnering
Halozyme Therapeutics, Inc.                                                                  Group of Quintiles Transnational)

3:00     Building the Plane While You’re Flying It: Organizational Design                    2:00     Managing an Effective Virtual Team
         and the Changing AM-PM Interface                                                    Claire Sookman, Principal, Strategic Operations, Virtual Team Builders
Harry Atkins, Senior Director, Alliance Management, Endo Pharmaceuticals, Inc.
                                                                                             2:30     High-Impact Influence: Building Strategic Relationships
Co-Presenting with:
                                                                                             Shanna Teel, Ph.D., Chief Executive Officer, Dr. Shanna Teel & Company
Steven Lyons, Senior Vice President, Project Management, Endo Pharmaceuticals, Inc.
                                                                                             3:00     Ice Cream Refreshment Break in the Exhibit Hall
3:30     Sponsored Presentation (Opportunity Available)
                                                                                                      (Last Chance for Viewing)
3:45     Networking Refreshment Break in the Exhibit Hall
                                                                                             3:40     Using a Web-Based Shared Knowledge Repository to Manage
4:30     The Interface with Project Management from an Alliance                                       Collaborative Projects
         Management Perspective                                                              Kenneth Abrams, Ph.D., Chief Operating Officer, Vice President of Knowledge Management
Paddy Padmanabhan, CA-AM, Senior Manager, Alliance Management, Daiichi Sankyo, Inc.          and User Experience, Visual Solutions
5:00     Project and Alliance Management in Generic                                          4:10     Tools and Best Practices for Managing the Alliance
         Pharmaceutical R&D                                                                           Management - Project Management Interface - A Panel
Jun Han, Ph.D., Global R&D Project Manager, Global R&D, Barr Pharmaceutical Inc.                      Discussion
                                                                                             Moderator: Kendra Eager, Ph.D., Assistant Vice President, Alliance Management, Wyeth
5:30     End of Day
                                                                                             Pharmaceuticals
                      THURSDAY, JUNE 11                                                      Panelists:
8:00 am – 4:00 pm Registration Open                                                          Katherine Mathes, Clinical Operations, Regional Account Leader, Eli Lilly and Company
8:00     Morning Coffee                                                                      Michael F. Haller, Vice President, Alliance Management & Portfolio Development,
                                                                                             Halozyme Therapeutics, Inc.
       ROLES, RESPONSIBILITIES, PROCESS                                                      Chad Nikel, Director, Market and Brand Leadership, Integrated Project Management
             AND BEST PRACTICES                                                              Jeremy Ahouse, Ph.D., Director, Alliance Management, Novartis Institutes for BioMedical
                                                                                             Research, Inc.
8:30     Chairperson’s Remarks
Chad Nikel, Director, Market and Brand Leadership, Integrated Project Management Co., Inc.

8:40     How to Deliver Results in Tough Economic Times
Chad Nikel, Director, Market and Brand Leadership, Integrated Project Management Co., Inc.

9:10     The Role of Alliance and Project Managers at Each Stage of
         Product Development
Laurie Dubrovin, PMP, Senior Project Manager, Product Portfolio Management, Genentech

9:40     From Plans to Practice – Maximizing the Delivery of
         Development Milestones Utilizing an Alliance and Project                                                  Alumni Discount -
         Management Partnership                                                                            Receive 25% Off Your Registration!
Katherine Mathes, Clinical Operations, Regional Account Leader, Eli Lilly and Company

10:10 Networking Coffee Break in the Exhibit Hall
                                                                                                                  t        t
                                                                                               Cambridge H ltht h I tit t (CHI) appreciates
                                                                                               C b id Healthtech Institute (CHI)  H          i t
                                                                                               your participation at our events. Through loyalty
10:55 Observing Alliances and Projects: What are you Looking For?
Jeremy Ahouse, Ph.D., Director, Alliance Management, Novartis Institutes for BioMedical        like yours, CHI has been able to build this congress
Research, Inc.                                                                                 into a must-attend event for senior level decision-
                                                                                               makers. As a result of the great loyalty you have
                                                                                               shown us, we are pleased to extend to you the
                                                                                               exclusive opportunity to save an additional 25% off
                                                                                               the registration rate.
                                                                                               Just check off the box marked Alumni Discount on
                                                                                               the registration form to receive the discount!
                                                                                               Please note: Our records must indicate that you were an attendee of a CHI conference.




                                                                        g
                                                          WorldPharmaCongress.com                                                                                                              7
                                                                                                                                                    Third Annual
                                                                                                              Cardiotoxicity and Drug Safety
                                                                                 Exploring Preclinical and Clinical Strategies for Early Assessment of Drug-Induced Cardiac Events
                                                                                                                              June 9-10
Drug Safety Summit Sponsored by Drug Safety Executive Council


                                                                                                                                                            2:45
                                                                                                                                                            2 45     I     d R tifi Ki 2 1 P t hX
                                                                                                                                                                     Inward Rectifier Kir2.1 PatchXpress
                                                                                         MONDAY
                                                                                         MONDAY, JUNE 8                                                              Assay as a Model of Cardiac IK1                   Sponsored by
                                                                        RECOMMENDED PRE-CONFERENCE SHORT COURSES*                                           John Imredy, Ph.D., Research FellowCellular Safety Investigations,
                                                                 9:00 am – 12:00 pm                                                                         Merck Research Labs
                                                                 (SC1) CARDIAC SAFETY: IMPROVING PRE-CLINICAL PREDICTIONS TO                                3:00     Grand Opening Refreshment Break in the Exhibit Hall
                                                                          BETTER CLINICAL OUTCOMES                                                          3:40     Use of Cardiac Troponin Measurements in Drug Development For
                                                                 2:00 – 5:00 pm                                                                                      the Detection of Cardiotoxicity
                                                                                                                                                            John K. Finkle, M.D., F.A.C.P., F.A.C.C., Cardiovascular Area Director, Global Clinical
                                                                 (SC4) ION CHANNEL ASSAYS FOR SAFETY SCREENING
                                                                                                                                                            Safety and Pharmacovigilance, GlaxoSmithKline
                                                                 See page 2 for details and a full list of short courses. *Separate Registration Required
                                                                                                                                                            4:10      In Vitro and In Vivo Models to Predict Cardiotoxicity:
                                                                 3:00 – 5:00 pm Main Conference Pre-Registration                                                      Where do we Stand?
                                                                                                                                                            Thomas Force, M.D., Professor of Medicine and Clinical Director of the Center for
                                                                MAIN CONFERENCE                                                                             Translational Medicine, Thomas Jefferson University
                                                                                          TUESDAY, JUNE 9                                                   4:40     Cardiotoxicity of Anti-Cancer Drugs: A Matter of Multiple Hits
                                                                                                                                                            Giorgio Minotti, M.D., Professor of Pharmacology, CIR and Drug Sciences, University
                                                                7:30 am – 6:00 pm Registration Open                                                         Campus Biomedico of Rome
                                                                7:30     Morning Coffee                                                                     5:10     Happy Hour in the Exhibit Hall
                                                                             PRECLINICAL STRATEGIES FOR                                                     6:10     End of Day
                                                                              EARLY RISK ASSESSMENTS                                                                             WEDNESDAY, JUNE 10
                                                                8:30     Chairperson’s Remarks                                                              7:30 am – 5:30 pm Registration Open
                                                                Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Abbott
                                                                                                                                                            7:30 – 8:30 Continental Breakfast Breakout Discussions
                                                                Laboratories
                                                                                                                                                            Table Seven: In Vitro and In Vivo Models to Predict Cardiotoxicity
                                                                 nts                                                                                        Moderator: Thomas Force, M.D., Professor of Medicine and Clinical Director of the Center
                                                                J. Rick Turner, Ph.D., PGCE, President and Chief Scientific Officer, Turner Medical           for Translational Medicine, Thomas Jefferson University
                                                                Communications LLC
                                                                                                                                                            •   How Reliable And Predictable Are These Models?
                                                                9:10    Mechanisms Underlying Sex Differences in the Susceptibility to                      •   Where Do We Stand In Terms Of Their Use And Applications?
                                                                        Torsade de Pointes in Drug-Induced Long QT 2
                                                                                                                                                            Table Eight: New Insights Into Clinical Cardiac Safety Testing
                                                                Guy Salama, Ph.D., Professor, Department of Cell Biology and Physiology, University of
                                                                                                                                                            Sashi Nadanaciva, Principle Scientist, Compound Safety Prediction, Pfizer Inc.
                                                                Pittsburgh School of Medicine
                                                                                                                                                            •   New Methodologies And Regulations For Clinical Safety
                                                                9:40     Value of Animals with Failing Heart and/or Ventricular Hypertrophy
                                                                                                                                                            •   Clinical Cardiac Biomarkers: Have They Proved Useful?
                                                                         for Increasing Ability to Detect Cardiovascular Effects of Drugs
                                                                Anusak Kijtawornrat, D.V.M., Ph.D., Laboratory Animal Resident, The Ohio State              Table Nine: Cardiac Safety Assessments: A Regulatory Perspective
                                                                University                                                                                  Moderator: Colette Strnadova, Ph.D., Senior Scientific Advisor, Therapeutic Products
                                                                                                                                                            Directorate, Health Canada
                                                                10:10   Networking Coffee Break
                                                                                                                                                            •   Strategies For Assessing Drug-Induced Cardiomyopathies -Cardiovascu-
                                                                10:40   Strategy for Preclinical Cardiovascular Safety Evaluation for                           lar Morbidity And Mortality Outcome Studies
                                                                        Biologicals
                                                                                                                                                            •   Use Of Dedicated ECG And Blood Pressure Studies
                                                                Hugo Vargas, Ph.D., Director, Investigative Safety Pharmacology, Amgen
                                                                11:10    Developing and Using a Scientific-Based Integrated Risk Assessment                             CLINICAL METHODOLOGIES FOR
                                                                         for Managing Drug Candidates in Early Development
                                                                Peter K.S. Siegl, Ph.D., Independent Consultant, Siegl Pharma Consulting LLC                           DETECTION OF ADVERSE EVENTS
                                                                                                                                                            8:30      Chairperson’s Remarks
                                                                11:40    Challenges of the Integrative Risk Assessment, the “Heart” of                      Philip Sager, MD, FACC, FAHA, Chief Medical Officer, CardioDx, Inc. and ICH E14
                                                                         Preclinical Cardiac Safety Evaluations                                             Implementation Group Topic Leader
                                                                Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Abbott
                                                                Laboratories                                                                                8:40     Post-Hoc Comparison of Alternative Analytical Methods in the Non-
                                                                                                                                                                     Inferiority Comparison of Drug to Placebo in a thorough QT Study
                                                                12:10 pm LUNCHEON PRESENTATION              Sponsored by                                    Charles M. Beasley, Jr., M.D., F.F.P.M., Chief Scientific Officer, Global Product Safety, Eli
                                                                The Yin and Yang in Label Free Measurement - Monitoring of Cor.At pure                      Lilly & Co.
                                                                Cardiomyocytes on the xCelligence Platform to Reveal Clinical Relevant
                                                                Drug Behaviour                                                                              9:10     Using Preclinical QT Data to Impact Clinical Study Design and
                                                                Heribert Bohlen, Ph.D., CEO, Axiogenesis AG                                                          Decision Making and Clinical Validation of Preclinical Models

                                                                12:40    LUNCHEON PRESENTATION                        Sponsored by                          Philip Sager, M.D., F.A.C.C., F.A.H.A., Chief Medical Officer, CardioDx, Inc. and ICH
                                                                                                                                                            E14 Implementation Group Topic Leader
                                                                1:10     Session Break
                                                                                                                                                            9:40      Sponsored Presentation (Opportunity Available)
                                                                          NOVEL APPROACHES FOR BETTER                                                       10:10 Networking Coffee Break in the Exhibit Hall
                                                                          PREDICTION OF CARDIOTOXICITY                                                      10:50 Cardiac Safety Assessments for Oncology Drugs: A Regulatory
                                                                                                                                                                      Perspective
                                                                1:40     Chairperson’s Remarks                                                              Colette Strnadova, Ph.D., Senior Scientific Advisor, Therapeutic Products Directorate,
                                                                J. Rick Turner, Ph.D., PGCE, President and Chief Scientific Officer, Turner Medical           Health Canada
                                                                Communications LLC
                                                                                                                                                            11:20 Improving Safety in Medical Products
                                                                1:45     Using Ex-vivo and In-vivo Assays for Assessing Cardiotoxicities                    Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, U.S. F.D.A.
                                                                         Beyond Ionic Channels
                                                                Huabin Sun, M.D., Senior Research Investigator, Cardiovascular Safety Pharmacology,         11:50 Panel Discussion
                                                                Discovery Toxicology, Bristol-Myers Squibb                                                  12:20 pm Close of Cardiotoxicity and Drug Safety Conference

                                                                2:15      Talk Title to be Announced
                                                                Craig T. January, M.D., Ph.D., Professor, Medicine and Physiology, Division of
                                                                                                       Wisconsin-Madison
                                                                Cardiovascular Medicine, University of Wisconsin Madison


8                                                                                                                                 g
                                                                                                                    WorldPharmaCongress.com
                                                                                   Second Annual
                                             Hepatotoxicity and Drug Safety
                    Exploring Preclinical and Clinical Strategies for Early Assessment of Drug-Induced Liver Injury
                                                              June 10-11




                                                                                                                                                                                      Drug Safety Summit Sponsored by Drug Safety Executive Council
                    WEDNESDAY, JUNE 10                                                    11:25   Strategies to Reduce NCE Hepatotoxicity Attrition Due to
                                                                                                  Mitochondrial Toxicity- Designing Novel Screening Methods
                                                                                          Sashi Nadanaciva, Principle Scientist, Compound Safety Prediction, Pfizer Inc.
                  KEYNOTE PANEL DISCUSSION
                                                                                          11:55  LUNCHEON PRESENTATION
                   DRUG SAFETY:                                                                  Sponsorship Opportunity Available or Lunch on Your Own
            STRIKING THE RIGHT BALANCE                                                    12:55 pm Session Break
             BETWEEN BENEFIT AND RISK
                                                                                                    NOVEL APPROACHES FOR BETTER
 2:00     KEYNOTE PANEL DISCUSSION
 Moderator: Peter K.S. Siegl, Ph.D., Independent Consultant, Siegl Pharma                           PREDICTION OF HEPATOTOXICITY
 Consulting LLC                                                                           1:25     Chairperson’s Remarks
 Participants:                                                                            Arie Regev, M.D., Hepatology Consultant and Chair, Liver Safety Committee, Global
 Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, U.S. FDA       Patient Safety, Eli Lilly and Company
 Colette Strnadova, Ph.D., Senior Scientific Advisor, Therapeutic Products Directorate,    1:30    Investigation of Drug-Induced Hepatotoxicity from a Drug
 Health Canada                                                                                    Metabolism Perspective
 Laszlo Urban, M.D., Ph.D., Executive Director, Global Head, Preclinical Safety           Wei Tang, Ph.D., Distinguished Senior Investigator, Department of Drug Metabolism and
 Profiling, Novartis Institutes for Biomedical Research Inc.                               Pharmacokinetics, Merck Research Laboratories
 Mitchell W. Krucoff, M.D. FACC, Professor of Cardiology and Director, CV Devices         2:00     The Liver Toxicity Biomarker Study: A Systems Biology Approach to
 Unit and eECG Core Lab, Duke Clinical Research Institute                                          Idiosyncratic Liver Toxicity
 Arie Regev, M.D., Hepatology Consultant and Chair, Liver Safety Committee, Global        James C. Fuscoe, Ph.D., Director, Center for Functional Genomics, U.S. F.D.A., National
 Patient Safety, Eli Lilly and Company                                                    Center for Toxicological Reasearch
                                                                                          2:30     Modeling Idiosyncratic Hepatotoxicity
3:30     Drug-Induced Nephrotoxicity – Multiplex                 Sponsored by             Michael McMillian, Ph.D., DABT, Principal Scientist, Mechanistic Toxicology, Johnson &
         Detection of Key Kidney Damage                                                   Johnson Pharmaceutical Research and Development
         Biomarkers in Rat Urine                                                          3:00     Ice Cream Refreshment Break in the Exhibit Hall
Scott Hayes, Ph.D., Research & Development Director, Assays, EMD Chemicals                         (Last Chance for Viewing)
3:45     Networking Refreshment Break in the Exhibit Hall                                 3:40     Causality and Severity Assessment in Idiosyncratic Drug
4:30     Early Prediction of Drug-Induced Hepatotoxicity. Where are We Now                         Induced Liver Injury
         and Where are We Going?                                                          Naga Chalasani, M.D., Professor, Director of Division of Gastroenterology and Hepatology,
Arie Regev, M.D., Hepatology Consultant and Chair, Liver Safety Committee, Global         Indiana University School of Medicine
Patient Safety, Eli Lilly and Company                                                     4:10    Talk Title To Be Announced
5:00     Once Initiated, How Does Liver Injury Progress?                                  Mark H. Steinberg, M.D., Senior Safety Medical Director, Patient Safety, AstraZeneca
Harihara M. Mehendale, Ph.D., Professor, Department of Toxicology, College of Pharmacy,   4:40    Repression of PXR Activity and CYP3A4 Expression in Populations
University of Louisiana at Monroe                                                                 with Proliferating Hepatocytes
5:30     End of Day                                                                       Taosheng Chen, Ph.D., Department of Chemical Biology and Therapeutics and Director,
                                                                                          HTS, St. Jude Children’s Research Hospital
                      THURSDAY, JUNE 11                                                   5:10     Close of Hepatotoxicity and Drug Safety Conference
8:00 am – 4:00 pm Registration Open
8:00   Morning Coffee

             PRECLINICAL STRATEGIES FOR
              EARLY RISK ASSESSMENTS
8:30     Chairperson’s Remarks
William B. Mattes, Ph.D., D.A.B.T., Director of Toxicology, The Critical Path Institute
8:40     Integration of Preclinical Studies into the Hepatic Safety
         Assessment Continuum
William B. Mattes, Ph.D., D.A.B.T., Director of Toxicology, The Critical Path Institute
9:10      In Vitro - In Vivo Correlations of Drug-Induced Liver Injury
Jinghai Xu, Ph.D., Director, Automated Biotechnology, Merck and Co.
9:40     The Challenges of Predicting Metabolism-Mediated Toxicity
         In Vitro
                                                                                                               About the Drug Safety
Frederic Moulin, DVM, Ph.D., Senior Research Investigator, Bristol-Myers Squibb                                  Executive Council
10:10    Networking Coffee Break in the Exhibit Hall
10:55    Translating Metabolomic Data into Mechanistic                                                             The Drug Safety Executive Council (DSEC) is a
         Understanding and Action: A Case Study                                                                   peer-to-peer membership of over 1,500 drug safety
Jeffrey W. Lawrence, Ph.D., Director, Investigative Toxicology, Amgen, Inc.                                       leaders with the common objective of advancing
                                                                                           the development of better and safer medicines. DSEC is driven by an
                                                                                           esteemed Advisory Board of industry executives representing many of the
                                                                                           largest and most prominent biopharmaceutical companies in the world.
                                                                                           Regular membership is complimentary and limited to current employees of
                                                                                           companies developing small and large molecule pharmaceuticals.
                                                                                                        For more information, visit www.drugsafetycouncil.org



                                                                         g
                                                           WorldPharmaCongress.com                                                                                                                              9
                                                                                                                                                        Inaugural
                                                                The Expanding Impact of New Animal Models in Drug Safety
                                                                                                                      Improving Predictability Through Novel Approaches
                                                                                                                                         June 9-10
Drug Safety Summit Sponsored by Drug Safety Executive Council



                                                                                           MONDAY, JUNE 8
                                                                                           MONDAY                                                              4 10
                                                                                                                                                               4:10         P
                                                                                                                                                                            Panel Discussion: Emerging Impact of Z b fish
                                                                                                                                                                                l Di     i    E    i   I       f Zebrafi h
                                                                                                                                                               Moderator: Ernie Bush, Ph.D., Vice President of Collaboration, DSEC
                                                                3:00 – 5:00pm Main Conference Pre-Registration
                                                                                                                                                               5:10     Happy Hour in the Exhibit Hall
                                                                MAIN CONFERENCE
                                                                                                                                                               6:10     End of Day
                                                                                           TUESDAY, JUNE 9                                                                         WEDNESDAY, JUNE 10
                                                                7:30 am – 6:00 pm Registration Open
                                                                                                                                                               7:30 am – 5:30 pm Registration Open
                                                                7:30 Morning Coffee
                                                                                                                                                               7:30 – 8:30 Continental Breakfast Breakout Discussions
                                                                    TEACHING AN OLD MODEL NEW TRICKS:                                                          Table Ten: Using in vitro Methods to Predict in vivo Toxicity
                                                                                                                                                               Moderator: Lawrence Vernetti, Ph.D., Director of Toxicology, Cellumen Inc.
                                                                        IMPROVING CURRENT MODELS                                                               •   Do you combine your in vitro results with other methods (e.g. toxicog-
                                                                8:30     Chairperson’s Remarks                                                                     enomics, model organisms)?
                                                                8:40     Early Prediction of Clinical Adverse Drug Reactions: in vitro                         •   Have you successfully used results from an in vitro assay to reprioritize
                                                                         Safety Pharmacology                                                                       compounds?
                                                                Laszlo Urban, Ph.D., Executive Director, Preclinical Safety Profiling, Novartis Institute for   •   What are the barriers to using in vitro toxicity assessment as a decision
                                                                Biomedical Research                                                                                tool during discovery?
                                                                9:10     Biomarkers of Functional Toxicities: Identification and                                Table Eleven:Accelerating Technology Adoption in Preclinical Drug Safety
                                                                         Assessment of their Translation into Humans                                           Moderator: To be announced
                                                                Jean-Pierre Valentin, Ph.D., Senior Director, Head of Safety Pharmacology, Astra-Zeneca        •   The ‘Not Invented Here’ mentality’s impact on new technology?
                                                                9:40     Assessing Cardiac Inotropic Liabilities of Early Discovery                            •   What can be done to lower the barriers for new technology or novel
                                                                         Compounds: A Practical Preclinical Approach                                               platform adoption?
                                                                Zhi Su, MD, Ph.D., Associate Research Investigator, Department of Integrative                  •   Can we simplify the technology evaluation process?
                                                                Pharmacology, Abbott Laboratories
                                                                                                                                                               Table Twelve: Animal Models – Where are We?
                                                                10:10 Networking Coffee Break                                                                  Moderator: Ernie Bush, Ph.D., Vice President of Collaboration, DSEC
                                                                                                                                                               •   What improvements have been made in animal models for
                                                                      NEW STUDIES IN CARCINOGENICITY                                                               toxicity testing?
                                                                    TESTING: BETTER WORK WITH RODENTS                                                          •   Where do we need to go and how do we get there?
                                                                10:40 Integration of a Comparative Modeling Approach into Cancer                               •   Are Zebrafish the answer? If not what is?
                                                                      Drug Development                                                                         •   What new biomarkers should be included in routine toxicity studies?
                                                                Melissa C. Paoloni, DVM, DACVIM (Oncology), Comparative Oncology Program,
                                                                National Cancer Institute, NIH                                                                      FAILING EARLIER: NOVEL APPROACHES
                                                                11:10    Interlaboratory Evaluation of Genomic Signatures                                                FOR BETTER PREDICTABILITY
                                                                         for Predicting Carcinogenicity in the Rat
                                                                Michael McMillian, Ph.D., Principal Scientist, Mechanistic Toxicology Preclinical              8:30     Chairperson’s Remarks
                                                                Drug Evaluation, Johnson & Johnson                                                             D. Lansing Taylor, Ph.D., President and Chief Executive Officer, Cellumen

                                                                11:40 Sources of Variation Toxicogenomics Study Control Animals                                8:40     Employing Surrogates and Transgenic Animals in
                                                                      Across Multiple Labs                                                                              Biotherapeutic Toxicology Assessments
                                                                Chris Corton, Ph.D., Sr. Rsch Biologist, Environmental Carcinogenesis Division, National       Tim MacLachlan, Ph.D., Associate Director of Nonclinical Safety Assessment, Genzyme
                                                                Health and Environmental Effects Research Lab, US Environmental Protection Agency              Corporation

                                                                12:10 pm LUNCHEON PRESENTATION                                                                 9:10     Predictive Methodologies in Ophthalmic Pharmaceutical
                                                                            Sponsorship Opportunity Available or Lunch on Your Own                                      Discovery and Safety
                                                                                                                                                               Robert Peiffer, D.V.M., Ph.D., D.A.C.V.O., Senior Investigator, Merck and Co.
                                                                1:10     Session Break
                                                                                                                                                               9:40     Better Anticipate Toxicity in Humans Using Mitostream®: a
                                                                ZEBRAFISH & OTHER ALTERNATIVE MODELS:                                                                   Biomic Assay for Mitochondrial Behavior           Sponsored by
                                                                                                                                                               Nathalie A. Compagnone, Ph.D., CEO-CSO, ICDD-sas
                                                                       THE LATEST AND GREATEST
                                                                1:40     Chairperson’s Remarks                                                                 10:10 Networking Coffee Break in the Exhibit Hall
                                                                Ernie Bush, Ph.D., Vice President of Collaboration, Drug Safety Executive Council              10:50 How Well do Animal Models Predict Adverse Effects in
                                                                                                                                                                     Humans?
                                                                1:45     Zebrafish Assays as Early Safety Pharmacology Screens:
                                                                                                                                                               Vivek Kadambi, Ph.D., Senior Director, Drug Safety Evaluation, Millennium
                                                                         Paradigm Shift or Red Herring?                                                        Pharmaceuticals
                                                                Jean-Pierre Valentin, Ph.D., Senior Director, Head of Safety Pharmacology, Astra-Zeneca
                                                                                                                                                               11:20 Closing Panel Discussion: What can we do to Create Better
                                                                2:15     Using the 3Rs to Develop Predictive Models for Preclinical
                                                                                                                                                                     Testing Models so that Toxicity Results in Animals are more
                                                                         Safety Assessment
                                                                                                                                                                     Predictive?
                                                                Kathryn Chapman, Ph.D., Program Manager, National Centre for the Replacement,
                                                                                                                                                               Moderator: Jack Reynolds, D.V.M., D.A.C.V.P., D.A.C.L.A.M. & F.I.A.T.P.,
                                                                Refinement and Reduction of Animals in Research, NC3R’s
                                                                                                                                                               Chairman of the Advisory Board, Drug Safety Executive Council
                                                                2:45     Validation of an Automated Screening Platform                      Sponsored by       Panelists:
                                                                         in Zebrafish
                                                                                                                                                               Tim MacLachlan, Ph.D., Associate Director of Nonclinical Safety Assessment, Genzyme
                                                                Carles Callol-Massot, Scientific Director , Biobide S.L.
                                                                                                                                                               Corporation
                                                                3:00        Grand Opening Refreshment Break in the Exhibit Hall
                                                                                                                                                               Vivek Kadambi, Ph.D., Senior Director, Drug Safety Evaluation, Millennium
                                                                3:40     The Other Side of the Coin: Screening Environmental Toxicants                         Pharmaceuticals
                                                                         Using Zebrafish Embryos                                                                Robert Peiffer, D.V.M., Ph.D., D.A.C.V.O., Senior Investigator, Merck and Co.
                                                                Stephanie Padilla, Principal Investigator, Cellular & Molecular Toxicology Branch,
                                                                Neurotoxicology Division, Environmental Protection Agency                                      12:20 pm Close of the Expanding Impact of New Animal Models in
                                                                                                                                                                        Drug Safety Conference


10                                                                                                                    WorldPharmaCongress.com
                                                      Sponsorship and Exhibit Information

The World Pharmaceutical Congress delivers an international audience of senior level scientists and
executives from the biotech and pharmaceutical industries. In 2008, the Congress attracted over 400                                                                 2008 Sponsors & Exhibitors
delegates hailing from 23 countries.
                                                                                                                                                                    Applied Cell Sciences Inc.
       Attendee Demographics                                                                 2008 Company Type
                                                                                                                                                                    ASDI




                                                                                                               Government/Nat’l Labs
                                                                                                                                                                    Aureus Pharma




                                                                                                                                       Academic/ Hospital
                                                                                                                                                                    Axxam SpA

                                                       Research Scientist
                                   Senior Scientist




                                                                                              Pharmaceutical
                                                                                                                                                                    BD Biosciences-Bioimaging
                                                                                                                                                                    Systems
                                   Manager/
                        Director




                                                                                   Biotech
              C-Level




                                                                                                                                                            Other
                                                                                                                                                                    BIOBIDE SL
                                   M




                                                                                                                                                            O
                        D




                                                       R
                                   S
              C




      4%    15%         20%        29%                32%
                                                                                                                                                                    BioFocus DPI
                                                                                  39%        33%               13%                     11%                  4%

                                                                                                                                                                    Biomol
Sponsorship Opportunities                                                      User Group Meetings
                                                                                                                                                                    Cellular Dynamics
Sponsorship packages are designed to put you                                   Co-locate your user group meeting with the World
                                                                                                                                                                    International
face to face with your target audience. Many                                   Pharmaceutical Congress. CHI will help market the
allow for speaking opportunities as part of the                                event, manage logistical operations, develop the
                                                                                                                                                                    Cellumen
main conference agenda, allowing you to engage                                 agenda, and more. CHI can handle the entirety of
hard to reach prospects while delivering updates                               the meeting, or aspects of your choosing.
                                                                                                                                                                    Corning Incorporated
and information about your latest products or
                                                                               Other Networking and
services.                                                                                                                                                           DiscoverX
                                                                               Promotional Opportunities:
Agenda Presentations                                                           • Badge Lanyards Sponsor (exclusive)
Speak to a captive audience about your latest                                  • Exhibit Hall Reception                                                             Elsevier
technology. Package includes a 15-minute podium                                • Hotel Room Door Hanger (1 night exclusive)
presentation within the scientific agenda, exhibit                              • Hotel Room Drop                                                                    Emka Technologies
space, on-site branding, and access to cooperative                             • Keynote Chair Drop
marketing efforts by CHI.                                                      • Specific Conference Chair Drop                                                      Evotec Inc.
                                                                               • Padfolio Sponsor
Breakfast & Luncheon Workshops                                                 • Refreshment Break                                                                  Fluxion Biosciences
Invite session attendees to enjoy breakfast or                                 • Tote Bag Sponsor
lunch on your company’s behalf while you give                                  • Tote Bag Insert                                                                    GE Healthcare
your talk. Includes a 30-minute presentation and                               • Program & Exhibit Guide Sponsor (exclusive)
                                                                                                                                                                    GeneGo
concludes with a 15-minute Q&A session.
                                                                               Exhibitor Information
                                                                                                                                                                    Kinovate Life Sciences,Inc.
Invitation-Only VIP Dinner                                                     Exhibitors at the World Pharmaceutical Congress
Hand-pick your top prospects for a night of                                    will enjoy facilitated networking opportunities with                                 Marriott Vacation Club
networking at a premier local venue. Sponsors                                  over 400 high-level decision-makers. Speak face to                                   Internationa
will enjoy face-to-face networking in a relaxed and                            face with prospective clients and showcase your
collaborative atmosphere. CHI will work closely                                latest product, service or solution.                                                 Mathworks
with you to develop an invitation format and guest
list.                                                                          Exhibitor Benefits Include:                                                           Meso-Scale
                                                                               • One booth space (8’D x10’W)
Focus Groups                                                                   • Corporate URL link on conference website and                                       Millipore
Conduct market research and gather feedback                                      proceedings
on a new product or idea from industry experts                                 • Discounted rate for additional participants                                        Molecular Devices
by running a focus group on-site at the World                                  • 30 word corporate description in Program
Pharmaceutical Congress. CHI will work closely                                   Guide                                                                              Multispan
with you to execute this exclusive gathering.                                  • Co-operative promotional mailing campaign
                                                                                 o Create awareness of your involvement                                             PharmaDirections, Inc.
                                                                                    at CHI events to your prospective clients,
                                                                                    colleagues, and current customers and offer                                     ReachBio LLC
                                                                                    a special discount off the registration fee.
                                                                                    CHI Marketing Managers will customize an                                        RegeneMed, Inc.
                                                                                    invitation letter, market to your prospects
                                                                                    and pay postage costs.                                                          Schrodinger, Inc
                                                                               • Corporate listing in final brochure
                                                                               • One full conference registration (booth &                                          Simulations Plus
          For more sponsorship &                                                 session access)
                                                                               • One booth only personnel registration                                              ToxiKon
         exhibit information contact:
                                                                                 (no access to sessions)
              Suzanne Carroll                                                  • One-time use of post conference delegate
       Manager, Business Development                                             mailing list through third party mail house,
                                                                                 (does not include printing, mailing or
                781-972-5452
                                                                                 processing charges)
          scarroll@healthtech.com



                                                                                          g
                                                                            WorldPharmaCongress.com                                                                                               12
                                                                           Distinguished Faculty
Timothy A. Esbenshade, Ph.D., Senior                  Michael Vitek, Ph.D., Chief Executive Officer,         Scott D. Bembenek, Ph.D., Senior Scientist,           Ronald C. Hawley, Ph.D., Principal Research
Group Leader, Neuroscience Research, Global           Neurology and Neuroscience, Cognosci, Inc.            Computer Aided Drug Discovery,                        Scientist, Medicinal Chemistry, Roche Palo Alto
Pharmaceutical Research & Development,                                                                      Johnson & Johnson PRD, LLC
Abbott Laboratories                                   Ernie Bush, Ph.D., Vice President, Collaborative                                                            Yama Abassi, Ph.D., Senrior, Director,
                                                      Projects, Drug Safety Executive Council               J. Guy Breitenbucher, Ph.D., Research Fellow,         Cell Biology, Roche/ACEA
Gary Gintant, Ph.D., Senior Group Leader,                                                                   Team Leader, Pain and Related Disorders,
Department of Integrative Pharmacology,               Jack Reynolds, Ph.D., Chairman, Advisory              Johnson & Johnson Pharmaceutical Research             Michael McMillian, Ph.D., Principal Scientist,
Abbott Laboratories                                   Board, Drug Safety Executive Council                  & Development                                         Mechanistic Toxicology Preclinical Drug
                                                                                                                                                                  Evaluation, Johnson & Johnson
Michael F. Jarvis, Ph.D., Volwiler Research           Mitchell W. Krucoff, M.D. FACC, Professor of          Alec D. Lebsack, Ph.D., Senior Scientist,
Fellow, Project Leader, Neuroscience Research,        Cardiology and Director, CV Devices Unit and          Medicinal Chemistry, Johnson & Johnson                Dominic di Giorgio, Director, Alliance
Abbott Laboratories                                   eECG Core Lab, Duke Clinical Research                 Pharmaceutical Research & Development                 Management, Schering-Plough
                                                      Institute
Zhi Su, MD, Ph.D., Associate Research                                                                       Frank Striggow, Ph.D., KeyNeurotek                    Paul D. Ratcliffe, Ph.D., Research Scientist,
Investigator, Department of Integrative               Charles M. Beasley, Jr., M.D., F.F.P.M.,              Pharmaceuticals AG                                    Team Leader, Schering-Plough Corporation
Pharmacology, Abbott Laboratories                     Chief Scientific Officer, Global Product Safety,
                                                      Eli Lilly & Co.                                       Erik M. Schaefer, Ph.D., Site Director, Signal        Julio Caso, M.D., Vice President,
Lauren Costantini, Ph.D., Vice President, Clinical                                                          Transduction Center, Cellular Analysis Business       Global Medical Affairs, Sepracor
Development, Accera, Inc.                             Katherine Mathes, Clinical Operations, Regional       Unit, Life Technologies
                                                      Account Leader, Eli Lilly & Co.                                                                             Taosheng Chen, Ph.D., Director, Assistant
Andreas Jeromin, Ph.D., Manager, Methods                                                                    Jeffrey S. Mogil, Ph.D., Professor,                   Member, Chemical Biology and Therapeutics, St.
Development, Allen Institute for Brain Science        Arie Regev, M.D., Hepatology Consultant and           McGill University                                     Jude Children’s Research Hospital
                                                      Chair, Liver Safety Committee, Global Patient
Michael Boedigheimer Ph.D., Principal Scientist,      Safety, Eli Lilly & Co.                               Ryan McGuinness, Senior Application Scientist,        Keith Foster, M.A., Ph.D., Founder and Head of
Amgen, Inc.                                                                                                 Drug Discovery, MDS Analytical Technologies           Technology Development, Syntaxin Limited
                                                      Stephanie Padilla, Principal Investigator, Cellular
Sue Stempien, Director, Global Strategic Sourcing,    & Molecular Toxicology Branch, Neurotoxicology        Lynn Seely, M.D., Chief Medical Officer,               Mitchell Friedman, Ph.D., Director of Toxicology,
Amgen, Inc.                                           Division, Environmental Protection Agency             Medivation, Inc.                                      Nonclinical Safety & Efficacy,
                                                                                                                                                                  Takeda Global Research & Development
Hugo Vargas, Ph.D., Director, Investigative Safety    Sharon Shacham, Ph.D. , Vice President of Drug        David J. Bell, Department of Automated
Pharmacology, Amgen, Inc.                             Development, Epix Pharmaceuticals                     Biotechnology, Merck and Company                      Claude M. Wischik, Ph.D.,
                                                                                                                                                                  TauRx Therapeutics, Ltd.
Sharon Zhao, Ph.D., Senior Scientist, Lead            Maurice Whelan, Ph.D., Head of HTS Facility,          Robert Peiffer, D.V.M., Ph.D., D.A.C.V.O.,
Discovery, Amgen, Inc.                                Institute for Health and Consumer Protection,         Senior Investigator, Merck and Company                William B. Mattes, Ph.D., D.A.B.T.,
                                                      European Commission Joint Research Centre                                                                   Director of Toxicology, The Critical Path
Elfrida Benjamin, Ph.D., Principal Investigator,                                                            Jinghai Xu, Ph.D., Director, Automated                Institute
Pharmacology, Amicus Therapeutics                     Andreas Scheel, Group Leader, Cellular Assays,        Biotechnology, Merck and Company
                                                      Evotec AG                                                                                                   Harihara M. Mehendale, Ph.D., Professor,
Steven W. Andrews, Ph.D., Associate Director of                                                             Xiaohua Douglas Zhang, Associate Director,            Department of Toxicology, College of Pharmacy,
Drug Discovery, Array BioPharma Inc.                  David Brewster, Ph.D., D.A.B.T, Vice-President,       Merck Research Laboratories                           University of Louisiana at Monroe
                                                      Non-Clinical Safety,
David Brott, Ph.D., Principal Scientist, Safety       F. Hoffmann La Roche Inc.                             Joseph L. Duffy, Ph.D., Director of Medicinal         David Craik, Ph.D., Professor, Institute for
Assessment, AstraZeneca Pharmaceuticals                                                                     Chemistry, Merck Research Laboratories                Molecular Bioscience, The University of
                                                      Shannon Hamilton, Senior Scientist,                                                                         Queensland
Jean-Pierre Valentin, Senior Director,                F. Hoffmann La Roche Inc.                             Wei Tang, Ph.D., Distinguished Senior
Head of Safety Pharmacology, AstraZeneca                                                                    Investigator, Department of Drug Metabolism and       Thomas Force, M.D., Professor of Medicine and
Pharmaceuticals                                       Ann Hoffman, Senior Principal Scientist,              Pharmacokinetics, Merck Research Laboratories         Clinical Director of the Center for Translational
                                                      F. Hoffmann La Roche Inc.                                                                                   Medicine, Thomas Jefferson University
Anthony Lassiter, M.D., Senior Medical Director,                                                            Vivek Kadambi, Ph.D., Senior Director,
Product Safety and Pharmacovigilance, Astellas        Laurie Dubrovin, PMP, Senior Project Manager,         Drug Safety Evaluation, Millennium                    J. Rick Turner, Ph.D., PGCE, President and
                                                      Product Portfolio Management, Genentech               Pharmaceuticals                                       Chief Scientific Officer, Turner Medical
Jun Han, Ph.D., Global R&D Project Manager,                                                                                                                       Communications LLC
Global R&D, Barr Pharmaceutical Inc.                  Judith Marquis, Ph.D., Group Vice President,          Neal Gliksman, Senior Applications Scientist,
                                                      Pharmacology and Preclinical Development,             Molecular Devices                                     Giorgio Minotti, M.D., Professor of Pharmacology,
Elisabeth Pook, Ph.D., Senior Scientist, Lead         Genzyme Corporation                                                                                         CIR and Drug Sciences, G. d’Annunzio Univeristy
Discovery, Bayer Schering Pharma AG                                                                         Anthony Holmes Ph.D., Program Manager,                of Chieti-Pescara, Italy
                                                      Joanna F. Haas, M.D., M.S., Vice President,           National Centre for the Replacement,
Harry Witchel, Ph.D., Senior Lecturer in              Pharmacovigilance, Genzyme Corporation                Refinement and Reduction of Animals in                 Jie Zheng, Ph.D., Associate Professor, Physiology
Physiology, Brighton and Sussex Medical                                                                     Research                                              and Membrane Biology, University of California
School, United Kingdom                                Tim MacLachlan, Ph.D., Associate Director                                                                   at Davis School of Medicine
                                                      of Nonclinical Safety Assessment,                     James C. Fuscoe, Ph.D., Director, Center for
Huabin Sun, M.D., Senior Research Investigator,       Genzyme Corporation                                   Functional Genomics, U.S. F.D.A.,                     Douglas R. Galasko, Ph.D.,Professor in
Cardiovascular Safety Pharmacology, Discovery                                                               National Center for Toxicological Reasearch           Residence, University of California-San Diego
Toxicology,                                           John K. Finkle, M.D., F.A.C.P., F.A.C.C.,
Bristol-Myers Squibb                                  Cardiovascular Area Director, Global Clinical         Steven J. Greco, Ph.D., Senior Scientist,             Craig T. January, M.D., Ph.D., Professor,
                                                      Safety and Pharmacovigilance, GlaxoSmithKline         Neurotez, Inc.                                        Medicine and Physiology, Division of
Jack Santos, M.S. C.S., CIO, Executive                                                                                                                            Cardiovascular Medicine, University of
Strategist, Executive Advisory Program,               Kalpana Patel, Ph.D., Investigator, Cell              Jack Pearson, Global Vice President, Alliance         Wisconsin-Madison
Burton Group                                          Technology, GlaxoSmithKline                           Management, NovaQuest (The Partnering Group
                                                                                                            of Quintiles Transnational)                           Wendy Sanhai, Ph.D., Senior Scientific Advisor,
Mark Maier, Ph.D., Pharma Development                 Thierry Groblewski, Ph.D., AstraZeneca R&D                                                                  Office of the Commissioner, U.S. FDA
Toxicologist, Health Risk Management, Cambrex                                                               Berengere Dumotier, Ph.D., Preclinical
                                                      Michael F. Haller, Vice President of Alliance         CardioSafety Expert, Safety Pharmacology,             Aron H. Lichtman, Ph.D., Associate Professor,
Kenneth A. Stauderman, Ph.D., Vice President,         Management and Portfolio Development,                 Novartis Pharma AG                                    Pharmacology & Toxicology,
Research, CalciMedica, Inc.                           Halozyme Therapeutics, Inc.                                                                                 Virginia Commonwealth University
                                                                                                            Jeremy Ahouse, Ph.D., Director, Alliance
Robert Spencer, Ph.D., Senior Director, Preclinical   Colette Strnadova, Ph.D., Senior Scientific            Management, Novartis Institutes for                   Claire Sookman, Principal, Strategic Operations,
Development, Cara Therapeutics, Inc.                  Advisor, Therapeutic Products Directorate,            BioMedical Research, Inc.                             Virtual Team Builders
                                                      Health Canada
Dorothée Hallier-Vanuxeem, Ph.D, Development                                                                Laszlo Urban, Ph.D., Executive Director,              Kenneth Abrams, Ph.D., Chief Operating
Manager, R&D, Cellial Technologies                    Sasha Latypova, Executive Vice President,             Preclinical Safety Profiling, Novartis Institute for   Officer, Clinical Best Practices, Visual Solutions
                                                      iCardiac                                              Biomedical Research                                   Dartmouth Hitchcock Medical Center
D. Lansing Taylor, Ph.D., President and Chief
Executive Officer, Cellumen Inc.                       Naga Chalasani, M.D., Professor, Director of          Douglas S. Johnson, Ph.D., Senior Principal           Raj Singh, Ph.D., President & Chief Executive
                                                      Division of Gastroenterology and Hepatology,          Scientist, Medicinal Chemistry,                       Officer, R&D, Vivo Biosciences, Inc.
Lawrence Vernetti, Ph.D., Director of Toxicology,     Indiana University School of Medicine
Cellumen Inc.                                                                                               Pfizer Global Research & Development
                                                                                                                                                                  Kendra Eager, Ph.D., Assistant Vice President,
                                                      Edward Tobinick, M.D., Director, Medicine,            Yvonne Will, Ph.D., Senior Scientist, Exploratory     Alliance Management, Wyeth Pharmaceuticals
George C. McCormick Ph.D., DABT, Vice                 Institute for Neurological Research, A Private
President : Drug Safety & Disposition,                                                                      Safety Differentiation-Cell Based Assays, Pfizer
                                                      Medical Group, Inc.                                   Global Research & Development                         Michael W. Leach, D.V.M, Ph.D., D.A.C.V.P.,
Cephalon, Inc.                                                                                                                                                    Assistant Vice President, Exploratory Drug Safety,
                                                      Chad Nikel, Director, Market and Brand                Gjumrakch Aliev, M.D., Ph.D., Research                Wyeth Research
Gilbert Rishton, Ph.D., Channel Island’s              Leadership, Integrated Project Management
Alzheimer’s Institute                                                                                       Associate, Professor of Cardiovascular and
                                                      Co., Inc.                                             Neuropathology, Biology, The University of            Melissa C. Paoloni, DVM, DACVIM
Riqiang Yan, Ph.D., Associate Professor,                                                                    Texas at San Antonio                                  (Oncology), Comparative Oncology Program,
                                                      Lisa Minor, Ph.D., Principal Scientist,                                                                     National Cancer Institute, NIH
Neurosciences, Cleveland Clinic Lerner                Drug Discovery, Johnson & Johnson
Research Institute                                                                                          Axel Olsen, Ph.D., Executive Director,
                                                                                                            Pharmacovigilance and Risk Management,
                                                                                                            Quintiles




                                                                                   g
                                                                     WorldPharmaCongress.com                                                                                                                           13
REGISTRATION INFORMATION                                                                             REGISTER 3 — 4th IS FREE                                                              Yes! I would like to receive a
                                           YES! Register me for the
                                           World Pharmaceutical Congress              9600 F         Individuals must register for the same conference or                                FREE eNewsletter subscription to:
❒ Mr. ❒ Ms. ❒ Mrs. ❒ Dr. ❒ Prof.                                                                     conference combination and submit completed registration
                                                                                                     forms together for discount to apply. Please reproduce this     ❒
Name                                                                                                 registration form as needed.
                                                                                                                                                                         The latest industry news, commentary
Job Title                                                                                  Div./Dept.                                                                    and highlights from Bio•IT World
Company
                                                                                                                                                                     ❒
Address                                                                                                                                                                  Innovative management in clinical trials
City/State/Postal Code
                                                                                                                                                                    ❒
Country
                                                                                                                                                                         Informatics tools and strategies
Telephone                                                                                                                                                                driving decisions

Fax                                                                                                                                                                        PRESENT A POSTER AND SAVE $50
Email*                                                                                                                                                              Cambridge Healthtech Institute encourages
*Email is not a mandatory field. However, by excluding your email you will not receive notification about online access to pre-conference                             attendees to gain further exposure by
presenter materials, conference updates, networking opportunities and requested eNewsletters.                                                                       presenting their work in the poster sessions.
How would you prefer to receive notices from CHI: EMAIL: ❒ Yes ❒ No                            FAX: ❒ Yes ❒ No                                                      To secure a poster board and inclusion in
                                                                                     COMMERCIAL                    ACADEMIC, GOVERNMENT                             the conference CD, your abstract must be
                                                                                                                      HOSPITAL-AFFILIATED                           submitted, accepted and registration paid in
PRE-CONFERENCE SHORT COURSE PRICING (June 8)                                                                                                                        full by May 1, 2009. Register online to use the
Single Short Course                                                                      ❒ $645                               ❒ $345                                Poster Abstract Submission form or, if you
Two Short Courses                                                                        ❒ $945                               ❒ $545                                register by phone, fax, or mail, you will receive
Short Course + Conference                                                                ❒ $100 off                           ❒ $100 off                            Poster Abstract Submission guidelines via
Add a short course to your conference registration and SAVE $100                                                                                                    e-mail.
REQUIRED – Please select the short course(s) you will attend                                                                                                        Title:
9am-12pm                                                                 2pm-5pm
❒ (SC1) CARDIAC SAFETY                                                   ❒ (SC4) ION CHANNEL ASSAYS FOR SAFETY SCREENING
❒ (SC2) HIGH CONTENT SCREENING                                           ❒ (SC6) ANIMAL MODELS OF PAIN
❒ (SC3) AVOIDING PITFALLS IN ALZHEIMER’S CLINICAL TRIAL DESIGN
CONFERENCE PRICING                                                                                                                                                  Please Send Related Conference Information :
 Single Conference Package     (Includes access to 2 conference days, excludes short courses)                                                                       ❒ POST-APPROVAL DRUG SAFETY (PHV)
Early Registration until March 13                                           ❒ $1,245                         ❒ $625                                                 ❒ MASTERING MEDICINAL CHEMISTRY (MCH)
Advance Registration until May 1                                            ❒ $1,395                         ❒ $695
After May 1 and on-site                                                     ❒ $1,595                         ❒ $795                                                CHI Insight Pharma Reports
REQUIRED – Please select the one conference you’re most likely to attend                                                                                           A series of diverse reports designed to keep life
June 9-10                                                                   June 10-11                                                                             science professionals informed of the salient
❒ Targeting Pain with Novel Therapeutics                                    ❒ Targeting Alzheimer’s with Novel Therapeutics                                        trends in pharmaceutical technology, business,
❒ Cell-Based Assays for HTS                                                 ❒ Integrating Effective Alliance Management                                            clinical development, and therapeutic disease
❒ Cardiotoxicity and Drug Safety                                            ❒ Hepatotoxicity and Drug Safety                                                       markets. For a detailed list of reports, visit
❒ Animal Models in Drug Safety                                                                                                                                     InsightPharmaReports.com or contact Rose
 Multiple Conference Package (Includes access to 3 conference days, excludes short courses)                                                                        LaRaia, rlaraia@healthtech.com, 781-972-5444.

Early Registration until March 13                                       ❒ $1,645                                          ❒ $795                                   Barnett International
Advance Registration until May 1                                        ❒ $1,795                                          ❒ $875                                   Barnett is a recognized leader in clinical
After May 1 and on-site                                                 ❒ $1,995                                          ❒ $945                                   education, training, and reference guides for
REQUIRED – Please select the two conferences you’re most likely to attend                                                                                          life science professionals involved in the drug
June 9-10 (Choose One)                                                    June 10-11 (Choose One)                                                                  development process. For more information,
❒ Targeting Pain with Novel Therapeutics                                  ❒ Targeting Alzheimer’s with Novel Therapeutics                                          visit barnettinternational.com
❒ Cell-Based Assays for HTS                                               ❒ Integrating Effective Alliance Management
                                                                                                                                                                   Additional Registration Details
❒ Cardiotoxicity and Drug Safety                                          ❒ Hepatotoxicity and Drug Safety
                                                                                                                                                                   Each registration includes all conference
❒ Animal Models in Drug Safety
                                                                                                                                                                   sessions, posters and exhibits, food functions,
DISCOUNTS (Below discount offers cannot be combined)                                                                                                               and a copy of the conference CD.
❒ Alumni Save 25%
Poster Discount                                                                      ❒ $50 off                                                                     Group Discounts
DSEC Member Discount                                                                 ❒ $100 off                                                                    Special rates are available for multiple attendees
Hotel Incentive*                                                                     ❒ $100 off                                                                    from the same organization. Contact David
*Registration must include a short course, plus multiple conference package, and hotel reservations must be booked under the World                                 Cunningham at 781-972-5472 to discuss your
Pharma Congress room block for a minimum of three nights. My Loews Philadelphia Hotel Confirmation number is                                                        options and take advantage of the savings.
❒ I cannot attend but would like to purchase the World Pharmaceutical Congress CD for $750 (plus shipping).
   Massachusetts delivery will include 5% sales tax.                                                                                                                     Handicapped Equal Access
❒ Please send information on exhibiting and opportunities to present workshops.                                                                                    In accordance with the ADA, Cambridge
PAYMENT INFORMATION                                                                                                                                                Healthtech Institute is pleased to arrange special
❒ Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.                                            accommodations for attendees with special needs.
❒ Invoice me, but reserve my space with credit card information listed below. Invoices unpaid two weeks prior to conference will be billed                         All requests for such assistance must be submitted
   to credit card at full registration rate. Invoices must be paid in full and checks received by the deadline date to retain registration discount.               in writing to CHI at least 30 days prior to the start of
   If you plan to register on site, please check with CHI beforehand for space availability.                                                                       the meeting.
❒ Please charge: ❒ AMEX (15 digits) ❒ Visa (13-16 digits) ❒ MasterCard (16 digits)
                                                                                                                                                                   Substitution/Cancellation Policy
Card #                                                                                                  Exp. Date                                                  In the event that you need to cancel a
Cardholder                                                                                                                                                         registration, you may:
                                                                                                                                                                   • Transfer your registration to a colleague within
Signature
                                                                                                                                                                     your organization
Cardholder’s Address (if different from above)                                                                                                                     • Credit your registration to another Cambridge
City/State/Postal Code                                                                                                                                               Healthtech Institute program
                                                                                                                                                                   • Request a refund minus a $100 processing fee per
Country                                                                                                                                                              conference.
  Please refer to the Registration Code below:                                                                                                                     • Request a refund minus the cost ($750) of
                                                                                                                                                                     ordering a copy of the CD
            Please refer to the Keycode below:                                                                                                                     NOTE: Cancellations will only be accepted up to
                                                                                                                                                                   two weeks prior to the conference.

                                                                                                                                                                   Program and speakers are subject to change.

                                                                                                                                                                   Video and or audio recording of any kind is
                                                                                                                                                                   prohibited onsite at all CHI events.


                                                                                                                                                                   Fax or Mail Registration to:
                                                                                                                                                                      Cambridge Healthtech Institute
                                                                                                                                                                   250 First Avenue, Suite 300, Needham, Massachusetts 02494
                                                                                                                                                                   T: 781-972-5400 or Toll-free in the U.S. 888-999-6288

                                                                   WorldPharmaCongress.com                                                                         F: 781-972-5425 • www.healthtech.com
                                                                                                                              DRUG
                                                                                                                              SAFETY
ONLINE CAMBRIDGE HEALTHTECH INSTITUTE OFFERS AN EXPANSIVE SUITE
                   of information resources specific to Drug Safety. Follow these links for articles, social networking,
                   research, seminars and conferences all pertaining to Drug Safety.

                                                       Cambridge Healthtech Institute
                                                       Launches Drug Safety Series
Drug Safety                                            of Conferences
Insights from                                                                           For the past 16 years, Cambridge Healthtech Institute (CHI)
                                                            CONFERENCES
Bio-IT World                                                     HEALTHTECH.COM
                                                                                       has developed over 800 conferences, which have attracted
                                                                                       over 70,000 attendees from around the world. CHI strives to
                            Bio-IT World               develop quality programs that provide valuable new insights and competing points of view
                          magazine – CHI’s             while offering balanced coverage of the latest developments.
                          flagship publication            CHI’s portfolio of conferences has grown to over 100 per year and remains focused on the
                          – publishes critical         latest trends in the biotech and pharmaceutical industries, with comprehensive coverage on
                          insight, analysis, and       Biomarkers, Personalized Medicine, Clinical Trials, Proteins and Proteomics, Drug Discovery
                          opinion on the tools         & Development, IT and Informatics, Chemistry, Diagnostics and Business.
                          and results of predic-          Fifth Annual Preclinical Drug Safety             Biomarker World Congess
                          tive biology, drug              World Pharmaceutical Congress                    Drug Safety Summit
                          discovery, informat-
                          ics, clinical research,
                          and personalized
medicine, in addition to the strategic deci-
sions made by companies in this area. Please
visit www.bio-itworld.com to view feature
articles, white papers, and podcasts on the life                                                          Insight Pharma Reports
sciences industry and to subscribe to
the magazine.
                                                                                                          Targets Cardiotoxicity
  Two insightful and informative articles
                                                                                                          and Biomarker SOPs
focusing on Drug Safety are below. Please                                                                   Insight Pharma Reports is the e
click on each article link to read.                                                                       premier life science informa-
   GSK Moving Upstream with Signal                     Barnett Seminars Keep                              tion provider. Insight Pharma
                                                                                                          Reports offer unparalleled
   Detection
   By Deb Borfitz (August 2008)
                                                       You Informed on the                                coverage of key issues in drug
                                                       Latest in Regulatory                               discovery and development.
   Safety Last                                                                                            Our reports are used by lead-
   By Mark Uehling (December 2004)                     and Drug Safety Issues                             ing pharmaceutical, biotech,
                                                                                        Your premier      diagnostic, and other life science companies
                                                                                      source for clini-   to keep abreast of the latest developments
                                                                                      cal trials train-   in pharmaceutical R&D and their potential
 STAY INFORMED with free eNewsletters
                                                       ing! The leader in quality training resources      applications and business impacts. The
 focusing on the life sciences industry from           for industry professionals of all levels in        reports are written by experts in consulting
 Cambridge Healthtech Media group -                    clinical trials, drug safety and development,      and industry, and are supported by hun-
 www.chimediagroup.com. Subscribe today!               medical devices, project management, regu-         dreds of hours of primary and secondary
                                                       latory compliance and research and statis-         research. Insight Pharma Reports provide
 The latest industry news, commentary and              tics. We offer a variety of training resources     comprehensive coverage of salient issues in
 highlights from Bio IT World.                         including live and web seminars, publica-          a concise, well-organized format.”
                                                       tions and customized on-site training.               Cardiotoxicity: Issues, Technologies,
 Innovative management in clinical trials.
                                                          Drug Development and FDA                          and Solutions for the Future
                                                          Regulations                                       Biomarker SOPs: Getting
                                                          Meeting International Safety                      Optimum Value from Your
 Informatics tools and strategies driving decisions.
                                                          Reporting Requirements                            Biomarker Programs


                           The Drug Safety Executive Council (DSEC) is a peer-to-peer membership of over 1,500 drug safety
                           leaders with the common objective of advancing the development of better and safer medicines.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:40
posted:7/22/2011
language:English
pages:14